Thao K . Huynh, PharmD , BCOP

Approaches that pair anti-TIGIT antibodies with other immune checkpoint inhibitors have sparked interest among investigators. Results of early-stage studies evaluating these unique combinations were recently presented at the American Association for Cancer Research Annual Meeting 2021. Later-stage studies are ongoing.

Research characterizing the relationship between this heterogeneity and response to targeted therapies can lead to improved selection of patients who will benefit from specific therapies.

Although chemotherapy is the mainstay of systemic treatment for advanced cholangiocarcinoma, there are limited treatment options when the disease progresses

As the understanding of genetic risk factors in breast cancer continues to grow, professional organizations have sought to provide specific recommendations for genetic testing that would prevent overtesting yet still diagnose as many mutations as possible in patients.

PARP inhibitors have propelled the field of metastatic castration-resistant prostate cancer forward as the next class of therapeutics to advance outcomes.

Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.

The use of agents targeting Bruton tyrosine kinase have moved into the standard of care for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in recent years. New data have indicated that more effective therapy by way of combination regimens and newly approved agents may further improve the prognosis of this disease.